Ascorbic Acid
Active ingredient: Ascorbic Acid
In short: Ascorbic acid injection is indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. Limitations of Use Ascorbic acid injection is not indicated for the treatme
What is Ascorbic Acid used for?
Ascorbic acid injection is indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated.
Limitations of Use
Ascorbic acid injection is not indicated for the treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.
Ascorbic Acid dosage
Ascorbic acid injection vials contain 25,000 mg, 5,000 mg or 2,500 mg of ascorbic acid and the largest recommended single dose is 200 mg. Do not give the entire contents of the vial to a single patient.
Do not administer ascorbic acid injection as an undiluted intravenous injection.
Minimize exposure to light because ascorbic acid injection is light sensitive.
Ascorbic acid injection is supplied as a Pharmacy Bulk Package (PBP) which is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion:
a. Use only in a suitable ISO Class 5 work area such as a laminar flow hood (or an equivalent clean air compounding area)
b. Penetrate each PBP vial closure only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. Given that pressure may develop within the vial during storage, exercise caution when withdrawing contents from the vial.
c. Once the closure system has been penetrated, complete all dispensing from the PBP vial within 4 hours. Each dose must be used immediately. Discard unused portion.
d. Prior to administration,
ascorbic acid injection must be diluted in a suitable infusion solution and the final solution for infusion must be isotonic (undiluted the osmolarity of ascorbic acid injection is approximately 5,900 mOsmol/L). Prior to preparing the admixture for infusion, calculate the osmolarity of the intended admixture for infusion. Add one daily dose of ascorbic acid injection directly to an appropriate volume of a suitable infusion solution (e.g., 5% Dextrose Injection, Sterile Water for Injection) and add appropriate solutes, as necessary, to make the final solution isotonic. Sterile Water for Injection is highly hypotonic; adjust solute content, as necessary, to make the final infusion solution isotonic prior to injection. Do not mix ascorbic acid injection with solutions containing elemental compounds that can be reduced (e.g., copper). The concentration of ascorbic acid in the final, admixture solution for infusion is to be the range of 1 mg to 25 mg of ascorbic acid per mL. For example, for the largest recommended dose:
Add 200 mg of ascorbic acid (equivalent to 0.4 mL of ascorbic acid injection) to 7.5 mL of Sterile Water for Injection to produce an infusion solution having an approximate osmolarity of 290 mOsmol/L. In this specific example, addition of solute is NOT necessary because the solution is isotonic.
e. Prepare the recommended dose based on the patient population .
f. Visually inspect for particulate matter and discoloration prior to administration (the diluted ascorbic acid injection solution should appear colorless to pale yellow).
g. …
How to take Ascorbic Acid — instructions & advice from the label
Inform patients that treatment with ascorbic acid injection may increase their risk of oxalate nephropathy .
Inform patients that treatment with ascorbic acid injection may impact laboratory results, including blood and urine glucose tests, up to 24 hours after infusion .
Inform patients with glucose-6-phosphate dehydrogenase deficiency that treatment with ascorbic acid injection may increase their risk of hemolysis .
Warnings & precautions
Do not take this medicine if: None.
Acute and chronic oxalate nephropathy have been reported with prolonged administration of high doses of ascorbic acid. Acidification of the urine by ascorbic acid may cause precipitation of cysteine, urate or oxalate stones. Patients with renal disease including renal impairment, history of oxalate kidney stones, and geriatric patients may be at increased risk for oxalate nephropathy while receiving treatment with ascorbic acid. Pediatric patients less than 2 years of age may be at increased risk for oxalate nephropathy during treatment with ascorbic acid because their kidneys are immature . Monitor renal function in patients at increased risk receiving ascorbic acid injection. Discontinue ascorbic acid injection in patients who develop oxalate nephropathy and treat any suspected oxalate nephropathy.
Ascorbic acid injection is not indicated for prolonged administration (the maximum recommended duration is one week) .
Hemolysis has been reported with administration of ascorbic acid in patients with glucose-6-phosphate dehydrogenase deficiency. Patients with glucose-6-phosphate dehydrogenase deficiency may be at increased risk for severe hemolysis during treatment with ascorbic acid. Monitor hemoglobin and blood count and use a reduced dose of ascorbic acid injection in patients with glucose-6-phosphate dehydrogenase deficiency . Discontinue treatment with ascorbic acid injection if hemolysis is suspected and treat as needed.
Ascorbic acid may interfere with laboratory tests based on oxidation-reduction reactions, including blood and urine glucose testing, nitrite and bilirubin levels, and leucocyte count testing. If possible, laboratory tests based on oxidation-reduction reactions should be delayed until 24 hours after infusion of ascorbic acid injection .
Ascorbic Acid side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Oxalate nephropathy and Nephrolithiasis
Hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency
The following adverse reactions associated with the use of ascorbic acid were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure:
Administration site reactions: pain and swelling.
Ascorbic acid injection should not be rapidly administered. Rapid intravenous administration (> 250 mg/minute) of ascorbic acid injection may cause temporary faintness or nausea, lethargy, flushing, dizziness, and headache (the recommended infusion rates of diluted ascorbic acid injection solution are 1.3 mg/minute (Pediatric Patients age 5 months to less than 12 months), 3.3 mg/minute (Pediatric Patients age 1 year to less than 11 years) and 33 mg/minute (Adults and Pediatric Patients 11 years and older) ).
Acute and chronic oxalate nephropathy have occurred with prolonged administration of high doses of ascorbic acid . In patients with glucose-6-phosphate dehydrogenase deficiency severe hemolysis has occurred .
Drug interactions
Ascorbic acid may decrease activities of erythromycin, kanamycin, streptomycin, doxycycline and lincomycin. Bleomycin is inactivated in vitro by ascorbic acid. If the antibiotic efficacy is suspected to be decreased by concomitant administration of ascorbic acid injection, discontinue ascorbic acid injection administration.
Ascorbic acid may acidify the urine and lower serum concentrations of amphetamine by increasing renal excretion (as reflected by changes in amphetamine urine recovery rates). In case of decreased amphetamine efficacy discontinue ascorbic acid injection administration. Standard monitoring of therapy is warranted.
In addition, acidification of urine by ascorbic acid will alter the excretion of certain drugs affected by the pH of the urine (e.g., fluphenazine) when administered concurrently. It has been reported that concurrent administration of ascorbic acid and fluphenazine has resulted in decreased fluphenazine plasma concentrations. Standard monitoring of therapy is warranted. …
About this medicine
Ascorbic acid injection, USP for intravenous use is a colorless to pale yellow, preservative-free, hypertonic, sterile, non-pyrogenic solution of ascorbic acid. Ascorbic acid injection must be diluted with an appropriate infusion solution (e.g., 5% Dextrose Injection, Sterile Water for Injection) .
The chemical name of ascorbic Acid is L-ascorbic acid. The molecular formula is C6H8O6. It has the following structural formula:
Each ascorbic acid injection USP, 50 mL, Pharmacy Bulk Package vial contains 25,000 mg ascorbic acid, USP equivalent to 28,125 mg sodium ascorbate.
Each ascorbic acid injection USP, 10 mL Pharmacy Bulk Package vial contains 5,000 mg ascorbic acid, USP equivalent to 5,625 mg sodium ascorbate.
Each ascorbic acid injection USP, 5 mL Pharmacy Bulk Package vial contains 2,500 mg ascorbic acid, USP equivalent to 2,812.5 mg sodium ascorbate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f0b683f8-189b-4a3f-9ffe-f91df6d798b6. Read the full official label on DailyMed.